| Literature DB >> 30557576 |
Magali Saez-Ayala1, Elsie Laban Yekwa2, Clémence Mondielli3, Loic Roux4, Sergio Hernández3, Fabrice Bailly5, Philippe Cotelle6, Dominga Rogolino7, Bruno Canard3, François Ferron3, Karine Alvarez8.
Abstract
Arenaviridae is a viral family whose members are associated with rodent-transmitted infections to humans responsible of severe diseases. The current lack of a vaccine and limited therapeutic options make the development of efficacious drugs of high priority. The cap-snatching mechanism of transcription of Arenavirus performed by the endonuclease domain of the L-protein is unique and essential, so we developed a drug design program targeting the endonuclease activity of the prototypic Lymphocytic ChorioMeningitis Virus. Since the endonuclease activity is metal ion dependent, we designed a library of compounds bearing chelating motifs (diketo acids, polyphenols, and N-hydroxyisoquinoline-1,3-diones) able to block the catalytic center through the chelation of the critical metal ions, resulting in a functional impairment. We pre-screened 59 compounds by Differential Scanning Fluorimetry. Then, we characterized the binding affinity by Microscale Thermophoresis and evaluated selected compounds in in vitro and in cellula assays. We found several potent binders and inhibitors of the endonuclease activity. This study validates the proof of concept that the endonuclease domain of Arenavirus can be used as a target for anti-arena-viral drug discovery and that both diketo acids and N-hydroxyisoquinoline-1,3-diones can be considered further as potential metal-chelating pharmacophores.Entities:
Keywords: Arenavirus; Diketo acids; Endonuclease domain; LCMV; Metal chelators; N-Hydroxyisoquinoline-1,3-diones; Polyphenols
Mesh:
Substances:
Year: 2018 PMID: 30557576 DOI: 10.1016/j.antiviral.2018.12.008
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970